6 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 6, Unknown 3, Not yet recruiting 1, Recruiting 1, Suspended 1 |
Follow Irinotecan: new trials by email Literature Review of Irinotecan trials Research Report on Irinotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Irinotecan, Etoposide, Cisplatin - Small Cell Lung Cancer | Phase 4 | Unknown | Guangdong Association of Clinical Trials | 308 | 2015-02-01 | 2016-12-05 |
| Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Oxaliplatin, Leucovorin Calcium, Irinotecan Hydrochloride - Esophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 4 | Suspended | University of Chicago | 36 | 2014-12-11 | 2026-03-30 |
| Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Thalidomide, CPT-11 - Gastric Cancer | Phase 4 | Unknown | Wang Jufeng | 900 | 2014-08-01 | 2015-03-30 |
| A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Oxaliplatin, Capecitabine, Bevacizumab - Colorectal Neoplasms | Phase 4 | Completed | Hoffmann-La Roche | 128 | 2012-06-26 | 2019-01-22 |
| Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype CPT-11, Raltegravir (Isentress®), Midazolam - Solid Tumor | Phase 4 | Completed | National University Hospital, Singapore | 25 | 2010-04-01 | 2012-11-01 |
| Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Irinotecan, 5FU, leucovorin - Stage IV Colorectal Cancer, Gastric Cancer | Phase 4 | Unknown | Asan Medical Center | 1500 | 2009-01-01 | 2019-01-29 |
| Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants irinotecan, 5 fluorouracil - Metastatic Colorectal Cancer | Phase 4 | Completed | Institut de Recherche Clinique sur les Cancers et le Sang | 71 | 2005-06-01 | 2010-07-20 |
| A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum 5-Fluorouracil, Bevacizumab, Irinotecan - Colorectal Cancer | Phase 4 | Completed | Hoffmann-La Roche | 40 | 2005-05-01 | 2017-03-09 |
| Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer capecitabine, fluorouracil, irinotecan hydrochloride - Colorectal Cancer | Phase 4 | Completed | Centre Hospital Regional Universitaire de Limoges | 200 | 2005-03-01 | 2011-05-16 |
| Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Irinotecan, Capecitabine - Upper Gastrointestinal Tumours | Phase 4 | Completed | Royal Marsden NHS Foundation Trust | 33 | 2003-01-01 | 2009-12-16 |
Colorectal Neoplasms (6) · Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (1) · Colonic Neoplasms (1) · Neutropenia (1) · Rectal Neoplasms (1) · Small Cell Lung Carcinoma (1)
Hoffmann-La Roche (2) · Asan Medical Center (1) · Centre Hospital Regional Universitaire de Limoges (1) · Gruppo Oncologico del Nord-Ovest (1) · Guangdong Association of Clinical Trials (1) · Institut de Recherche Clinique sur les Cancers et le Sang (1) · National University Hospital, Singapore (1) · Pfizer (1) · Royal Marsden NHS Foundation Trust (1) · University of Chicago (1) · Wang Jufeng (1)
France (3) · Australia (2) · China (2) · South Korea (2) · United Kingdom (2) · United States (2) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1)
Boon Cher Goh, MRCP (1) · Chiara Cremolini, MD, PhD (1) · Daniel Catenacci (1) · David Cunningham (1) · Gilles Freyer, MD (1) · Guo Yanzhen (1) · Nicole Tubiana-Mathieu, MD (1) · Qin Yanru (1) · Shun Lu, M.D (1) · Wang Jufeng (1) · YongSang Hong, Professor (1) · Zhang Zhongmian (1) · Zhou Yun (1)
PMID 23497305, PMID 26808671, PMID 32058557, PMID 32142532, PMID 33912999
2023 (1), P30CA014599 (1)